In a phase Ib/IIa clinical study of 35 patients with mild-moderate COVID-19 related ARDS, EXO-CD24 showed promising efficacy and had a very favourable safety profile with no severe adverse events (SAEs) or even adverse events (AE) related to EXO-CD24 [31]. Here, CD24 is linked to COVID-19.